Online citations, reference lists, and bibliographies.
← Back to Search

Hyperlipidemia In Primary Gout.

T. Yue, D. Dorph, H. Smith
Published 1978 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
This paper references
On the mechanism of action of atromid-S on triglyceride transport in man.
E. Bierman (1970)
10.1056/NEJM197406062902306
Treatment of hyperlipidemia.
R. Levy (1974)
10.1172/JCI106290
Efcts of chronic ethanol feeding on serum lipoprotein metabolism in the rat.
E. Baraona (1970)
10.1161/01.CIR.45.1.114
Prevalence of Plasma Lipoprotein Abnormalities in a Free‐Living Population of the Central Valley, California
P. D. Wood (1972)
10.1177/009127006900900108
The clinical use of dextrothyroxine in hypercholesterolemic states. An eight-year appraisal.
B. Cohen (1969)
10.7326/0003-4819-66-5-851
Correlations of serum uric acid and lipid concentrations in normal, gouty, and atherosclerotic men.
T. Benedek (1967)
10.1016/0006-2952(76)90523-2
Hepatic triglyceride lipases--effect of clofibrate and halofenate.
R. Cenedella (1976)
10.1016/S0368-1319(69)80063-3
Effect of clofibrate on low-density lipoprotein turnover in essential hypercholesterolaemia.
P. J. Scott (1969)
10.1016/S0140-6736(77)92549-1
MATERNAL SERUM-ALPHA-FETOPROTEIN MEASUREMENT IN ANTENATAL SCREENING FOR ANENCEPHALY AND SPINA BIFIDA IN EARLY PREGNANCY: Report of U.K. Collaborative Study on Alpha-fetoprotein in Relation to Neural-tube Defects
N. Wald (1977)
10.1016/S0021-9150(74)80003-1
Comparison of the effects of clofibrate and halofenate (MK-185) in isolated rat hepatocytes.
C. Homcy (1974)
10.1056/NEJM197703172961106
Metabolic and Hepatic Effects of Alcohol
K. Isselbacher (1977)
10.1136/ard.32.6.501
Gout and its relation to lipid metabolism. I. Serum uric acid, lipid, and lipoprotein levels in gout.
H. Mielants (1973)
10.1002/cpt1970114551
The effect of MK‐185 on some aspects of uric acid metabolism
A. Jain (1970)
Quantitative analysis of uric acid in blood and urine; methods and interpretation.
Gutman Ab (1957)
10.1172/JCI101443
THE INTERRELATIONS OF SERUM LIPIDS IN NORMAL PERSONS.
J. P. Peters (1943)
10.1016/0002-9343(61)90220-0
Serum lipids, hypertension and coronary artery disease.
M. Albrink (1961)
Control of purine biosynthesis in normal and pathologic states.
E. Holmes (1975)
SERUM LIPIDS AND SERUM URIC ACID IN HUMAN TWINS.
J. Jensen (1965)
10.1016/S0140-6736(72)90738-6
Ischaemic heart-disease in relation to fasting values of plasma triglycerides and cholesterol. Stockholm prospective study.
L. Carlson (1972)
10.1172/JCI107331
Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction.
J. Goldstein (1973)
10.1172/JCI107904
Inhibition of hormone-stimulated lipolysis by clofibrate. A possible mechanism for its hypolipidemic action.
M. A. D'Costa (1975)
10.1136/ard.32.6.506
Gout and its relation to lipid metabolism. II. Correlations between uric acid, lipid, and lipoprotein levels in gout.
H. Mielants (1973)
10.1177/003591576605900409
Lipid metabolism in gout.
Barlow Ka (1966)
10.1161/01.CIR.47.3.558
Hyperlipoproteinemia: Prevalence in a Free‐Living Population in Albany, New York
D. Brown (1973)
10.1016/0026-0495(65)90005-3
Correlation of serum lipids with uric acid and blood sugar in normal males.
J. P. Dunn (1965)
10.1097/00000441-196410000-00001
CORONARY HEART DISEASE A PROSPECTIVE STUDY
M. Gertler (1964)
10.1161/01.CIR.39.5.675
Long‐Term Effects of Clofibrate (Atromid‐S) on Serum Lipids in Man
D. Hunninghake (1969)
10.1016/0065-2571(74)90025-9
The regulation of the pentose phosphate cycle in rat liver.
H. Krebs (1974)
10.1161/01.CIR.29.4.508
Hypertriglyceridemia in Gout
E. Feldman (1964)
10.1016/0026-0495(65)90111-3
STUDIES WITH ETHYL CHLOROPHENOXYISOBUTYRATE (CLOFIBRATE).
D. Azarnoff (1965)
Mechanisms of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia.
S. Grundy (1972)
10.1161/01.CIR.46.2.257
Systemic Arterial Blood Pressure during Exercise in Patients with Atherosclerosis Obliterans of the Lower Limbs
E. Lorentsen (1972)
10.1002/cpt1971123517
Hypolipidemic, uricosuric, and thyroxine‐displacing effects of MK‐185 (halofenate)
J. P. Morgan (1971)
10.1016/0026-0495(71)90097-7
Effects of chlorophenoxyisobutyrate on the synthesis and metabolism of cholesterol in man.
H. Sodhi (1971)
[Gout and hyperlipemia].
R. Günther (1967)
10.1016/0021-9150(73)90065-8
The uricosuric action of halofenate (MK-185) in patients with hyperuricemia or uncomplicated primary gout and hyperlipidemia.
J. C. Hutchison (1973)
10.7326/0003-4819-74-1-1
Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study.
W. Kannel (1971)
10.7326/0003-4819-87-3-386_2
Gout and uric acid metabolism.
J. Talbott (1970)
10.1152/AJPLEGACY.1970.218.5.1313
Effect of ethyl p-chlorophenoxyisobutyrate on rat adipose lipoprotein lipase activity.
E. Tolman (1970)
10.1016/S0140-6736(78)90925-X
DOES PREGNANCY PROTECT AGAINST OVARIAN CANCER?
V. Beral (1978)
10.1016/0026-0495(68)90099-1
Hypoglycemic and uricosuric properties of acetohexamide and hydroxyhexamide.
T. Yu (1968)
10.1016/S0016-5085(19)33499-7
Induced alterations in composition of bile of persons having cholelithiasis.
J. Thistle (1971)
10.1016/0002-9343(64)90088-9
SERUM CHOLESTEROL-TRIGLYCERIDE DISTRIBUTION IN A "NORMAL" NEW YORK CITY POPULATION.
L. Schaefer (1964)
10.1056/NEJM197602052940601
Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men.
G. Rhoads (1976)
10.1016/0021-9681(73)90103-3
The prevalence of hyperlipidemia in a natural community.
T. C. Gibson (1973)
10.1016/0002-9149(69)90401-9
Lipid and carbohydrate abnormalities in patients with angiographically documented coronary artery disease.
R. Heinle (1969)
10.1111/j.1532-5415.1975.tb00971.x
Mass Screening for Coronary Risk Factors in 2,524 Asymptomatic Adults
W. Aronow (1975)
10.1093/ajcn/13.1.1
Fasting and postprandial serum triglyceride levels in healthy young Americans.
D. Brown (1963)
10.1001/JAMA.1972.03200070084015
The coronary drug project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. The coronary drug project research group.
J. Stamler (1972)
10.1136/ard.33.4.298
Gout and hyperlipidaemia.
T. Gibson (1974)
10.1016/0021-9681(74)90079-4
Relation of weight change to changes in atherogenic traits: the Framingham Study.
F. Ashley (1974)
10.1172/JCI107560
Effects of weight reduction on obesity. Studies of lipid and carbohydrate metabolism in normal and hyperlipoproteinemic subjects.
J. Olefsky (1974)
10.1016/S0140-6736(75)91845-0
CLOFIBRATE AND GALLSTONES
J. Cooper (1975)
10.1016/0002-9343(74)90167-3
The importance of type IV hyperlipoproteinemia as a predisposing factor in coronary artery disease.
A. Salel (1974)
10.1016/0002-8703(74)90510-9
Plasma uric acid and body weight
J. T. Scott (1974)
10.1136/ard.31.6.487
Plasma lipid levels in gout.
L. Darlington (1972)
10.1210/JCEM-24-2-139
THE SEPARATE HYPOLIPOPROTEINEMIC EFFECTS OF DEXTROTHYROXINE AND ETHYL CHLOROPHENOXYISOBUTYRATE.
E. H. Strisower (1964)
10.1001/JAMA.1964.03070220062023
BLOOD LIPID AND URIC ACID INTERRELATIONSHIPS.
D. Berkowitz (1964)
10.1016/s0021-9258(18)74424-4
Variations in lipemia of normal subjects.
E. Man (1937)
10.1016/0026-0495(71)90115-6
Effect of chlorophenoxyisobutyrate on the metabolism of endogenous glycerides in man.
H. Sodhi (1971)
10.1016/S0368-1319(66)80036-4
Effects of chlorophenoxyisobutyrate (CPIB) on liver composition and triglyceride synthesis in rats
R. Gould (1966)
10.1016/0002-9343(76)90755-5
Drug treatment of hyperlipidemia.
D. Yeshurun (1976)
10.1016/0002-9149(74)90132-5
Serum lipoproteins and coronary heart disease.
G. Berenson (1974)
10.1001/JAMA.1975.03240160024021
Clofibrate and niacin in coronary heart disease.
J. Stamler (1975)
10.1016/0005-2760(75)90005-3
Effect of halofenate and clofibrate on lipid synthesis in rat adipocytes.
M. Greenspan (1975)
10.1016/S0140-6736(62)92423-6
EXPERIMENTAL EVALUATION OF AN ORALLY ACTIVE COMBINATION OF ANDROSTERONE WITH ETHYL CHLOROPHENOXYISOBUTYRATE
J. Thorp (1962)



This paper is referenced by
Association of Hyperuricemia and Dyslipidemia-A Potent Cardiovascular Risk Factor Authors
D. Lokanath (2014)
10.3390/genes10030246
The Interaction between Sex and Hyperlipidemia on Gout Risk Is Modulated by HLA-B Polymorphic Variants in Adult Taiwanese
Tsui-Wen Hsu (2019)
10.1007/978-1-4684-3584-9_6
Lipoproteins in Nutrition and Transport
S. Natelson (1980)
10.3390/ijerph18020387
Prevalence of Hyperuricemia and the Use of Allopurinol in Older Poles—Results from a Population-Based PolSenior Study
Mateusz Winder (2021)
10.1007/978-3-642-93422-3_26
Beziehung der Hyperurikämie zu anderen Krankheiten
G. Wolfram (1990)
10.1007/978-1-4615-5181-2_22
The Metabolic Syndrome
F. Leyva (1999)
10.1007/BF02283105
Renal excretion of urate by hyperuricaemic-hyperlipidemic patients
E. Estevéz (2005)
10.1007/s10067-020-05374-z
The anti-inflammatory properties of HDLs are impaired in gout
Yuan Wang (2020)
La hiperuricemia como factor pronóstico después de un síndrome coronario agudo
A. Lopez-Pineda (2017)
10.18632/oncotarget.20135
Recent advances on uric acid transporters
L. Xu (2017)
Factors associated with musculoskeletal disability and chronic renal failure in clinically diagnosed primary gout.
J. Alvarez-Nemegyei (2005)
10.3892/ijmm.2020.4501
Unraveling the genetic causes in large pedigrees with gout by whole-exome sequencing
Xiaoru Xia (2020)
10.1016/0049-0172(84)90016-7
Diversity of clinical features in gouty arthritis.
T. Yu (1984)
A Study of Correlation Between Uric Acid and Ejection Fraction in Heart Failure
Arun Kumar Tumuluri (2015)
10.1097/01.rhu.0000129082.42094.fc
Metabolic Syndrome and Ischemic Heart Disease in Gout
J. Vazquez-Mellado (2004)
10.5694/j.1326-5377.1984.tb132665.x
Therapeutics of hyperuricaemia and gout
B. Emmerson (1984)
10.1016/0049-0172(81)90094-9
Solid and liquid nourishment in gout: Selected historical excerpts, largely empiric or fashionable and current scientific? Concepts in the management of gout and gouty arthritis
J. H. Talbott (1981)
Diversity of Clinical Features in Gouty Arthritis
G. Levy (1984)
Semantic Scholar Logo Some data provided by SemanticScholar